ReNerve Reports Record Q4 FY26 Sales and Expansion
Key points
- Record quarterly sales of $211k
- Annual sales up 88%
- New distribution partnerships in Malaysia, Hong Kong, and Indonesia
- NervAlign Nerve Guide Matrix advances to Stage 3
- Secured $5M funding facility
Full summary
ReNerve Limited, an Australian biotechnology company, reported its Q4 FY26 activities, highlighting record sales of $211k, a 50% increase from the previous quarter. Annual sales reached $510k, up 88% from the previous year. The company expanded its commercial footprint with new distribution partnerships in Malaysia, Hong Kong, and Indonesia. Additionally, ReNerve secured a $5M funding facility and advanced its NervAlign Nerve Guide Matrix to Stage 3, moving closer to FDA submission. The company also expanded its manufacturing capacity for its Empliq product range with the appointment of J4 Biologics.
Summary generated by a large language model. Please interpret with care.